Results 231 to 240 of about 61,341 (287)

CONFIDENCE in the safety and efficacy of dual therapy with an SGLT‐2 inhibitor and finerenone in patients with chronic kidney disease and type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6097-6100, November 2025.
Panagiotis I. Georgianos, Theocharis Koufakis, Spyridon Arampatzis, Vassilios Liakopoulos   +3 more
wiley   +1 more source

Different aspects of pharmacological heart failure treatment. [PDF]

Eur Heart J Cardiovasc Pharmacother
Agewall S.
europepmc   +1 more source

PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?

, 2002
Femida Gwadry‐Sridhar, Malcolm Arnold, Barbara Weaver, Gordon Guyatt   +3 more
openalex   +1 more source

Lead-induced hypertension and cognitive dysfunction: brain amyloid pathology. [PDF]

Eur J Med Res
Zhang Y, Xu Y, Song Y, Wang Y, Chen M, Ji X, Lin Y, Gu S.   +7 more
europepmc   +1 more source

Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular o

, 2014
Nathan R. Hill, Daniel Lasserson, Bruce Thompson, Rafael Perera, Jane Wolstenholme, Peter Bower, Thomas Blakeman, David Fitzmaurice, Paul Little, Gene Feder, Qureshi NA, Maarten W. Taal, John Townend, Charles J. Ferro, Richard J. McManus, Richard Hobbs   +15 more
openalex   +1 more source

Assessment of the efficacy of spironolactone for COVID-19 ARDS patients

, 2021
Ayşın Ersoy, Bülent Barış GÜVEN, Tuna ERTÜRK, Fulya Yurtsever, Zöhre KARAMAN, Temel Güner, Özge KÖMPE   +6 more
openalex   +1 more source

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists. [PDF]

Rev Cardiovasc Med
Bozkurt B, Januzzi JL, Bansal S.
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. [PDF]

BMC Cardiovasc Disord
Wu J, Pei Y, Wu J, Huang Y.
europepmc   +1 more source

Spironolactone for Treatment of Female Pattern Hair Loss.

Journal of American Academy of Dermatology, 2020
L. Burns, Brianna De Souza, E. Flynn, D. Hagigeorges, M. Senna   +4 more
semanticscholar   +1 more source

The Impact of Cirrhosis Severity and Spironolactone on Sex Hormone Levels in Men. [PDF]

Gastro Hep Adv
Akin Belli A, Flikshteyn B, Ziv Y, Lu A, Luo G, Lebovics N, Sigal SH.   +6 more
europepmc   +1 more source